<DOC>
	<DOCNO>NCT01205477</DOCNO>
	<brief_summary>To investigate safety efficacy methylprednisolone infiltration anserine bursitis treatment</brief_summary>
	<brief_title>Safety Efficacy Methylprednisolone Infiltration Anserine Bursitis Treatment</brief_title>
	<detailed_description />
	<mesh_term>Bursitis</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Clinical diagnosis anserine bursitis Intraarticular pathology reflect pain medial part knee</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Anserine bursitis</keyword>
</DOC>